Andrew N. Schiff
CIK: 0001172252
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 11, 2026GLUE
Monte Rosa Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25.8K shares- - Jun 5, 2026ACRS
Aclaris Therapeutics, Inc.
Exercise(M)Direct11.6K shares- - Jun 4, 2026ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
42.4K shares- - Jun 4, 2026ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
11K shares- - Jun 13, 2025GLUE
Monte Rosa Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
30.7K shares- - Jun 6, 2025ACRS
Aclaris Therapeutics, Inc.
Exercise(M)Direct4.8K shares- - Jun 5, 2025ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
42.4K shares- - Jun 5, 2025ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
11.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  GLUE Monte Rosa Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,800 | - | - | Direct |
| Jun 5, 2026 |  ACRS Aclaris Therapeutics, Inc. | Exercise(M) | 11,580 | - | $0 | Direct |
| Jun 4, 2026 | ACRS Aclaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 42,350 | - | - | Direct |
| Jun 4, 2026 | ACRS Aclaris Therapeutics, Inc. | Award(A) Restricted Stock Units | 10,987 | - | - | Direct |
| Jun 13, 2025 | GLUE Monte Rosa Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 30,700 | - | - | Direct |
| Jun 6, 2025 | ACRS Aclaris Therapeutics, Inc. | Exercise(M) | 4,793 | - | - | Direct |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 42,350 | - | - | Direct |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | Award(A) Restricted Stock Units | 11,580 | - | - | Direct |
1-8 of 8 transactions
About SCHIFF ANDREW N
SCHIFF ANDREW N (SEC CIK 0001172252) files insider reports with the SEC as Director of Monte Rosa Therapeutics, Inc. (GLUE) and Director of Aclaris Therapeutics, Inc. (ACRS).
Signal8 holds 4 ownership filings by SCHIFF ANDREW N, all Form 4s, filed between Jun 9, 2025 and Jun 12, 2026. Those filings report 8 transactions, from Jun 5, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SCHIFF ANDREW N's filings is in WAYNE, PA.
Recent filings by SCHIFF ANDREW N
- Jun 11, 2026: Grant or award of GLUE derivative securities (Form 4, code A).
- Jun 5, 2026: Option exercise of ACRS shares (Form 4, code M).
- Jun 4, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
- Jun 13, 2025: Grant or award of GLUE derivative securities (Form 4, code A).
- Jun 6, 2025: Option exercise of ACRS shares (Form 4, code M).
Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)
- Bowen Matthew, Principal Accounting Officer
- Warmuth Markus, President & CEO
- Champoux Jennifer, Chief Operating Officer
- Townson Sharon, Chief Scientific Officer
- Behbahani Ali, Director
- Janku Filip, Chief Medical Officer